24 January 2024

Renowned Venture Capitalist and Angel Investor Daniel Gutenberg Joins Swiss Rockets AG’s Board of Directors and Invests in Promising Biotech Startups

Swiss Rockets AG, Switzerland's leading incubator and accelerator of biotech startup companies, is delighted to announce the appointment of Daniel Gutenberg to its Board of Directors. With an illustrious career marked by investments in 12 unicorns, Daniel Gutenberg brings a wealth of experience and a visionary approach to the company. In addition, he has also made strategic investments in several Swiss Rockets AG portfolio companies, recognizing their potential to drive groundbreaking advancements in society and healthcare.

Daniel Gutenberg, one of Switzerland's most active Venture Capitalists and Angel Investors, is known for his unique ability to identify and support unicorn startups even before they reach ten employees. His remarkable track record in growing successful companies has made him a prominent figure in the Swiss business community.

Daniel Gutenberg's journey in entrepreneurship began in 1991 when he founded Gutenberg Communication Systems. The company's success led to its acquisition by the Telindus Group in 2000, with Daniel Gutenberg assuming the CEO role within the acquiring organization. During this period, he was also a member of the prestigious Young Presidents Organization (YPO), providing him with invaluable connections and insights from influential figures like Jeff Bezos and Marc Andreessen.

In 2003, Daniel embarked on a new chapter as an investor and advisor to startups through the Swiss venture capital firm Venture Incubator Partners. His unwavering commitment to fostering innovation and supporting emerging businesses has earned him recognition within the industry. In 2011, the Swiss Private Equity & Corporate Finance Association (SECA) honored him as the Business Angel of the Year.

Additionally, Daniel Gutenberg serves as a Venture Partner at VI Partners, a renowned Swiss venture capital firm, where he has been instrumental in shaping the future of technology-driven enterprises. His extensive involvement in public and private companies and organizations like YPO reflects his dedication to fostering leadership and innovation at every level.

Recognizing the immense potential of Swiss Rockets AG's portfolio companies in driving positive societal impact and revolutionizing the healthcare system, Daniel Gutenberg has also made strategic investments in several of these startups. "I believe that the cutting-edge technologies being developed by Swiss Rockets AG's portfolio companies have the potential to bring about breakthrough results that will benefit society at large," said Daniel Gutenberg.

Daniel is also a co-founder of the Crypto Finance Conference in St. Moritz, Switzerland, and an esteemed member of the Circle of Investors of BrainsToVentures. His involvement in these initiatives underscores his commitment to advancing the frontiers of technology and finance.

Daniel Gutenberg is also a Member of the Board of Governors at Technion University in Israel.

Swiss Rockets AG is thrilled to welcome Daniel Gutenberg to its Board of Directors, and his insights and expertise will undoubtedly contribute significantly to the company's mission of accelerating biotech startups. His unrivaled experience, combined with his investments in Swiss Rockets AG's portfolio companies, aligns perfectly with Swiss Rockets AG's vision for the future.

"We are honored to have Daniel Gutenberg join our Board of Directors and invest in our portfolio companies," said Dr. Vladimir Cmiljanovic, CEO and Founder of Swiss Rockets AG. "His exceptional track record and unwavering dedication to the startup ecosystem make him an invaluable addition to our team. We look forward to benefiting from his guidance, expertise, and investments as we continue to support and elevate Switzerland's biotech industry."

Daniel Gutenberg's appointment to the Board of Directors at Swiss Rockets AG and his strategic investments mark a significant milestone in the company's journey toward becoming a global leader in biotech incubation and acceleration, focusing on delivering transformative results for society and healthcare.